Highlights
Profile claimed by owner
About
Personalized Cancer Therapy
Hide and Seq combines predictive and prognostic biomarkers to promote effective treatment for several types of cancer. The company is developing an in vitro diagnostic genomic signature that identifies which patients should be offered an alternative chemotherapy in first and second lines of treatment. Hide and Seq is developing a predictive assay for first-line therapy aimed at identifying chemotherapy resistance to paclitaxel (Taxol) in patients with metastatic ovarian cancer. A predictive genetic assay will offer physicians a personally tailored mode of treatment intended to increase treatment efficacy and survival.
Identity
| Name | Hide and Seq |
|---|---|
| Slug | hide-and-seq |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwKi8tt0JDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jan 2018 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ramat Gan |
| HQ address | Anna and Max Webb and Family Psychology Building, Ramat Gan, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesDiagnostics Devices
Target customers
Healthcare & Life SciencesHealthcareProvidersConsumersDemographics & FamilyWomen
Business models
B2B
Tags
personalizationbiomarkersoncologypatientspersonalized-medicinechemotherapywomendoctorsmedical-technologiesdiagnosticswomen-healthcancertreatments
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}